CMMB FY 2023 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$66,827

Operating Income

-$25M

Net Income

-$24M

EPS (Diluted)

$-8.22

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$22M

Total Liabilities

$5M

Stockholders' Equity

$17M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$66,827	-$57,773	-15.7%
Operating Income	-$25M	-$29M	+10.8%
Net Income	-$24M	-$28M	+12.4%